Cardiovascular Drug Development: Protocol Design and Methodology
Versandkostenfrei!
Nicht lieferbar
Table of contents:Drug Discovery and Development, John C. SombergDevelopment of Congestive Heart Failure TherapyBackground Therapy in Congestive Heart Failure Studies, Jeffrey S. BorerCongestive Heart Failure Trial Design, Raymond John LipickyAngiotensin-Converting Enzyme Inhibitors for Mortality Reduction in Congestive Heart Failure: Should Approval Be Granted for a Class Effect?, Jeffrey S. Borer and John C. SombergSudden Death in Congestive Heart Failure Trials, John C. SombergPanelThese multidisciplinary presentations provide information essential to devising effective drug protocols in ca...
Table of contents:
Drug Discovery and Development, John C. Somberg
Development of Congestive Heart Failure Therapy
Background Therapy in Congestive Heart Failure Studies, Jeffrey S. Borer
Congestive Heart Failure Trial Design, Raymond John Lipicky
Angiotensin-Converting Enzyme Inhibitors for Mortality Reduction in Congestive Heart Failure: Should Approval Be Granted for a Class Effect?, Jeffrey S. Borer and John C. Somberg
Sudden Death in Congestive Heart Failure Trials, John C. Somberg
Panel
These multidisciplinary presentations provide information essential to devising effective drug protocols in cardiovascular drug development, facilitating the approval process.
Guides researchers and developers through the government drug approval process, facilitating development, minimizing costs, and harmonizing international standards employed in the creation of vital new cardiovascular therapies!
Cardiovascular Drug Development
explores the delicate balance of efficacy and safety that cardiovascular therapy must achieve to gain regulatory approval
discusses the search for surrogates and the need in some areas for natural history endpoints
reviews optimum strategies for protocol design in the development of drugs to treat hypertension, cardiac arrhythmias, heart failure, coronary artery disease, and hypercholesterolemia and other lipid disorders
compares and contrasts the varying standards of evidence for drug approval in the United States, Europe, and Asia
and more!
Cardiovascular Drug Development will prove to be a valuable asset for cardiologists, pharmacologists and pharmacists, regulatory affairs specialists, and directors of research and development for pharmaceutical companies.
Drug Discovery and Development, John C. Somberg
Development of Congestive Heart Failure Therapy
Background Therapy in Congestive Heart Failure Studies, Jeffrey S. Borer
Congestive Heart Failure Trial Design, Raymond John Lipicky
Angiotensin-Converting Enzyme Inhibitors for Mortality Reduction in Congestive Heart Failure: Should Approval Be Granted for a Class Effect?, Jeffrey S. Borer and John C. Somberg
Sudden Death in Congestive Heart Failure Trials, John C. Somberg
Panel
These multidisciplinary presentations provide information essential to devising effective drug protocols in cardiovascular drug development, facilitating the approval process.
Guides researchers and developers through the government drug approval process, facilitating development, minimizing costs, and harmonizing international standards employed in the creation of vital new cardiovascular therapies!
Cardiovascular Drug Development
explores the delicate balance of efficacy and safety that cardiovascular therapy must achieve to gain regulatory approval
discusses the search for surrogates and the need in some areas for natural history endpoints
reviews optimum strategies for protocol design in the development of drugs to treat hypertension, cardiac arrhythmias, heart failure, coronary artery disease, and hypercholesterolemia and other lipid disorders
compares and contrasts the varying standards of evidence for drug approval in the United States, Europe, and Asia
and more!
Cardiovascular Drug Development will prove to be a valuable asset for cardiologists, pharmacologists and pharmacists, regulatory affairs specialists, and directors of research and development for pharmaceutical companies.